Evidence map›Paper›PMID 36928495›Full record

SynthesisAdvances in therapy2023

Clinical, Economic, and Patient-Reported Benefits of Connected Insulin Pen Systems: A Systematic Literature Review.

Iain Cranston, Vinayak Jamdade, Birong Liao, Rachel S Newson

Open access · hybridAbstract readSystematic Review
In one paragraph

Synthesis in Advances in therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.

  1. [Diabetes technology (Update 2026)].Wiener klinische Wochenschrift · 2026
    Guideline
  2. Guideline
  3. Trial
  4. Review
  5. Review
  6. Observational
  7. Review
  8. Review
  9. Observational
  10. Advances in Continuous Glucose Monitoring: Clinical Applications.Endocrinology and metabolism (Seoul, Korea) · 2025
    Review
  11. Connected Insulin Pens and Pen Caps: Expanding Diabetes Technology Access and Adoption.Diabetes spectrum : a publication of the American Diabetes Association · 2025
    Article
  12. Review
  13. Article
  14. Criteria for Personalised Choice of a Continuous Glucose Monitoring System: An Expert Opinion.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024
    Article
  15. Article
  16. Advances in diabetes technology within the digital diabetes ecosystem.Journal of managed care & specialty pharmacy · 2024
    Review
  17. Review
  18. Innovative Approaches to Enhance and Measure Medication Adherence in Chronic Disease Management: A Review.Medical science monitor : international medical journal of experimental and clinical research · 2024
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 3 countries.

Iain CranstonAcademic Department of Endocrinology and Diabetes, Portsmouth Hospitals University NHS Trust, Portsmouth, UK.ORCID 0000-0002-8354-9917
Vinayak JamdadeEli Lilly and Company, Bangalore, India.ORCID 0000-0002-1197-0446
Birong LiaoEli Lilly and Company, Indianapolis, USA.ORCID 0000-0002-6336-8940
Rachel S NewsonEli Lilly and Company, 60 Margaret Street, Sydney, NSW, 2000, Australia. newson_rachel@lilly.com.ORCID 0000-0002-2653-5797
Eli Lilly (United States) · USEli Lilly (India) · INPortsmouth Hospitals NHS Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe objective of this systematic literature review was to evaluate the available literature concerning the clinical, economic, and patient-reported benefits of insulin pen platforms, including connected insulin pens/caps/sleeves and insulin platforms, as well as mobile apps capable of receiving near real-time insulin dosing information.

methodsMedline and Embase databases and the Cochrane Library were searched for published literature between January 2015 and May 2021, and manual searches for conference abstracts from 2018 to May 2021 were performed. These searches were supplemented by internet searches for relevant literature and clinical trials. Study selection involved the population, intervention, comparator, outcomes, time frame, and study design outline. Included studies investigated connected insulin systems or connected caps/sleeves enabling pens to be connected, or apps able to connect to these systems, in individuals of all ages with type 1 or type 2 diabetes mellitus.

resultsSearches identified a total of 26 publications (mostly observational studies and conference abstracts) for inclusion, representing ten unique, predominantly small studies. Evidence in this field is still in its early stages, and only two randomized controlled trials met our inclusion criteria. Available results showed that connected insulin pens and their systems potentially helped reduce suboptimal insulin use and may therefore improve glycemic control. Satisfaction of people with diabetes with the technologies used was high, and economic benefits were noted. Features of effective connected insulin pen devices include simplicity of use and data upload/sharing, useful "point-of-care" alerts, and simple and understandable data presentation to facilitate more effective consultations.

conclusionsConnected insulin pen systems could be increasingly considered as part of routine clinical care for insulin-treated persons with diabetes who must manage the complexity of their daily insulin routine. Future research focusing on the way data obtained from these devices can be most effectively used alongside other information is urgently needed.

Indexed as

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2Hypoglycemic AgentsInsulinCost-Benefit AnalysisHumansInjections, SubcutaneousMobile ApplicationsPoint-of-Care SystemsRandomized Controlled Trials as TopicHypoglycemic AgentsInsulinConnected insulin pensDiabetes mellitusDigital healthEconomicsInsulin infusion systemsPatient-reported outcomesTreatment outcome

Identifiers

PMID36928495
PMCPMC10130105
OpenAlexW4327681303

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.